Company Encyclopedia
View More
name
BetaShares Holdings Pty Ltd.
DRUG.AU
News
View More

Americans are facing a growing healthcare crisis - and your medicines are at risk

The U.S. faces a healthcare crisis due to heavy reliance on imported pharmaceuticals, primarily from China and India, leading to shortages of critical medicines. Bipartisan Senate hearings have highlighted this issue, urging a rebuild of domestic drug manufacturing. The Trump administration and private sectors are taking steps to boost U.S. production, with initiatives like JPMorgan's $1.5 trillion security plan. The goal is to reduce dependence on imports, enhance domestic production, and create jobs, ensuring healthcare security.

MorningStar·
MorningStar·

China threatens US drug supply, report says allies could counter danger

A USIEA report highlights the U.S.'s vulnerability due to reliance on Chinese-made pharmaceuticals, suggesting friend-shoring with allies like Israel to mitigate risks. The report warns of potential supply chain disruptions, citing past incidents and the COVID-19 pandemic. It advocates for an FDA Abraham Accords Office to diversify supply chains and ensure economic security, public health, and diplomatic leadership. A bipartisan bill supports this initiative.

FOX Business·
FOX Business·

UK slashes 2026 drug rebate rate by one-third to win back pharma sentiments

The UK has reduced its innovative medicines rebate rate for 2026 to 14.5% under the VPAG scheme, down from 22.9% in 2025. This move aims to improve relations with the pharma industry and boost the UK's attractiveness for clinical trials and new medicine launches. The change follows a UK-US deal exempting UK pharmaceutical imports from US tariffs, with the UK increasing NHS spending on innovative drugs. Despite the positive step, further efforts are needed to enhance the UK's global competitiveness in the pharma sector.

Pharmaceutical Technology·
Pharmaceutical Technology·

UK pledges extra $2 billion NHS spend to avert Trump tariffs, FT says

The UK has pledged to increase NHS spending by $2 billion over three years to avoid US drug import tariffs. This deal aims to raise NHS medicine spending to 0.35% of GDP by 2028, as reported by the Financial Times. Reuters has not verified this report.

Reuters·
Reuters·

Pharmaceutical Safety Assessment Market to grow at 8.1%, reaching $11.32 billion in 2025 due to demand for preclinical research and outsourcing.

In Dublin, the global market for pharmaceutical safety assessment is on the rise, with a notable increase from $10.47 billion in 2024 to an estimated $11.32 billion in 2025. This growth showcases a Compound Annual Growth Rate (CAGR) of 8.1%. Factors contributing to this expansion include a surge in preclinical research demands, more stringent drug safety protocols, rising reliance on contract research organizations, and advancements in the field.

Unusual Whales·
Unusual Whales·
Posts
View More

Recursion Pharmaceuticals (RXRX) $Recursion Pharmaceuticals(RXRX.US) In-depth Research Report: From Phenotypic Screening to Vertical Integration—Revaluation After Exscientia Acquisition and the New Pa......

  • 0
© 2025 Longbridge｜Disclaimer